Since the discovery of sickle cell disease (SCD) in 1910, enormous strides have been made
in the elucidation of the pathogenesis of its protean complications, which has inspired recent …

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States,
and a global health problem. Pathological features of the abnormal hemoglobin (HbS) result …

Rationale: Heart failure with preserved ejection fraction (HFpEF) can arise from
hypertension‐induced cardiac remodeling. Monocyte/macrophage accumulation and …

Hydroxyurea is FDA‐approved and now increasingly used for children with sickle cell
anemia (SCA), but dosing strategies, pharmacokinetic (PK) profiles, and treatment …

Although patients with homozygous sickle cell anemia (SCA) carry both significant left atrial
(LA) remodeling and an increased risk of stroke, the prevalence of atrial arrhythmia (AA) has …

The application of modern ovarian reserve measures to women with sickle cell disease
(SCD) may help answer longstanding questions about whether SCD or hydroxycarbamide …

Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for many
malignancies, hemoglobinopathies, metabolic diseases, bone marrow failure syndromes …

Previous reports indicate that IL18 is a novel candidate gene for diastolic dysfunction in
sickle cell disease (SCD)–related cardiomyopathy. We hypothesize that interleukin-18 (IL …

Sickle cell disease (SCD) is caused by a single point mutation in the gene that codes for
beta globin synthesis, causing haemoglobin polymerisation, red blood cell stiffening and …

Cardiovascular disease is a major cause of mortality in patients with sickle cell disease
(SCD). Niss et al previously reported that cardiac magnetic resonance in 25 patients showed …